Published by Benjamin Chiou on 4th March 2024
(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.
URL: http://www.digitallook.com/dl/news/story/34128437/...